Hygieia Extends Series B Round to $22 Million with Participation from Strategic Investors

Livonia, Mich., May 2, 2023 – Hygieia, a digital therapeutics company for insulin therapy, is extending its Series B funding round to $22 million with a lead investment from Firstime Ventures and additional investment from two strategic partners.  

Hygieia is the maker of d-Nav®, the only FDA-cleared technology to autonomously adjust insulin dose recommendations to correspond to a patient’s changing insulin needs, providing people who inject their insulin with a closed-loop system functionality. Patients get the proper insulin dose at each injection, without the need for physician intervention. Studies have shown that nearly 90 percent of d-Nav patients have improved A1C levels within 90 days*, without increasing the risk for hypoglycemia**.

“This is a validation of our d-Nav Technology and its potential to expand the availability of closed-loop functionality for those who inject insulin, which is 90% of insulin users,” said Eran Bashan, CEO and co-founder of Hygieia.

With the recent caps on insulin co-pays, there has been good progress in reducing the cost barrier for insulin therapy. With d-Nav, dose is not a barrier either. Because the d-Nav Technology autonomously adjusts insulin dose recommendations at the time of injection, patients get the right dose without the need for weekly visits to a physician.

“More than eight million Americans use insulin to treat their diabetes. This additional investment enables us to explore additional ways to bring d-Nav Technology to more insulin users, for safe, effective insulin therapy,” Bashan said.

Hygieia is building the nation’s leading network of diabetes care centers driven by the d-Nav Technology. Hygieia’s d-Nav Clinical Partnership Program for endocrinology practices treating patients with type 2 diabetes is now in Michigan, Texas, Arizona, and North Carolina, with more states available soon. The program seamlessly fits into endocrinology practice operations to improve patient outcomes while providing an added revenue stream.

The d-Nav insulin management program is covered by Medicare, most commercial health plans, and many Medicaid plans. For more information, contact +1-734-743-2838.

About Hygieia/ d-Nav Insulin Management Program 

Hygieia is the developer of d-Nav®, the first FDA-cleared technology to autonomously adjust insulin doses directly to the patient. d-Nav’s AI-powered technology automatically interprets data and independently initiates insulin management. The d-Nav Insulin Management Program adds clinical support that helps people with type 2 diabetes adjust their insulin doses according to their body’s changing insulin needs. Studies have shown that nearly 90 percent of people using d-Nav report lower A1C in just three months* without increasing the risk for hypoglycemia**. The d-Nav Insulin Management Program has been peer-reviewed with studies published in leading medical journals. Hygieia is headquartered in Livonia, Michigan. Learn more at d-Nav.com. 

* John E Schneider et al. Impact of a Novel Insulin Management Service on Non-insulin Pharmaceutical Expenses. J Health Econ Outcomes Res. 2018 Feb 20;6(1):53-62. https://jheor.org/article/9783

** Richard M Bergenstal et al. Automated insulin dosing guidance to optimise insulin management in patients with type 2 diabetes: a multicentre, randomised controlled trial. Lancet 2019 Mar 16;393(10176):1138-1148. https://pubmed.ncbi.nlm.nih.gov/30808512/

Media Contact:

Debbie Reinheimer, debbie@reinheimerpr.com